EA201490401A1 - Фармацевтическая композиция окисленного авидина, подходящая для ингаляции - Google Patents

Фармацевтическая композиция окисленного авидина, подходящая для ингаляции

Info

Publication number
EA201490401A1
EA201490401A1 EA201490401A EA201490401A EA201490401A1 EA 201490401 A1 EA201490401 A1 EA 201490401A1 EA 201490401 A EA201490401 A EA 201490401A EA 201490401 A EA201490401 A EA 201490401A EA 201490401 A1 EA201490401 A1 EA 201490401A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhalation
pharmaceutical composition
oxidized avidin
avidin suitable
lungs
Prior art date
Application number
EA201490401A
Other languages
English (en)
Other versions
EA026453B1 (ru
Inventor
Рита Де Сантис
Original Assignee
Сигма-Тау Индустрие Фармасьютике Риуните С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. filed Critical Сигма-Тау Индустрие Фармасьютике Риуните С.П.А.
Publication of EA201490401A1 publication Critical patent/EA201490401A1/ru
Publication of EA026453B1 publication Critical patent/EA026453B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В изобретении описан окисленный авидин, подходящий для ингаляции, для кондиционирования легких, пораженных неоперабельными/диффузными заболеваниями, и обеспечивающий нацеленное действие биотинилированных терапевтических средств на легкие.
EA201490401A 2011-08-02 2012-07-25 Применение окисленного авидина для ингаляции EA026453B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11006338 2011-08-02
PCT/EP2012/064576 WO2013017494A1 (en) 2011-08-02 2012-07-25 Pharmaceutical composition of oxidised avidin suitable for inhalation

Publications (2)

Publication Number Publication Date
EA201490401A1 true EA201490401A1 (ru) 2014-05-30
EA026453B1 EA026453B1 (ru) 2017-04-28

Family

ID=46581966

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490401A EA026453B1 (ru) 2011-08-02 2012-07-25 Применение окисленного авидина для ингаляции

Country Status (18)

Country Link
US (1) US9872831B2 (ru)
EP (1) EP2739314B1 (ru)
JP (1) JP6019118B2 (ru)
KR (1) KR101966630B1 (ru)
CN (1) CN103717239B (ru)
AU (1) AU2012292229B2 (ru)
BR (1) BR112014002593B1 (ru)
CA (1) CA2842276C (ru)
DK (1) DK2739314T3 (ru)
EA (1) EA026453B1 (ru)
ES (1) ES2729549T3 (ru)
IL (1) IL230597A0 (ru)
MX (1) MX355177B (ru)
PL (1) PL2739314T3 (ru)
PT (1) PT2739314T (ru)
UA (1) UA114482C2 (ru)
WO (1) WO2013017494A1 (ru)
ZA (1) ZA201401921B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2941243A4 (en) 2013-01-04 2016-09-14 Massachusetts Inst Technology SURFACE BINDING IN THE ADMINISTRATION OF A MEDICAMENT ON NANOPARTICLE BASE IN A TISSUE
US20200179530A1 (en) * 2016-05-19 2020-06-11 University Of Miami Targeted delivery of therapeutic agents and imaging reagents to pancreatic cancer cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5384128A (en) * 1993-03-02 1995-01-24 University Of Alabama Research Foundation Method of and compounds for treatment for cystic fibrosis
JPH09501418A (ja) 1993-07-19 1997-02-10 アムジエン・インコーポレーテツド エアゾル化タンパク質の安定化
NZ337924A (en) * 1997-02-20 2002-09-27 Klaus Kimmeldirk Site-specific drug delivery compounds comprising an anchoring moiety, a linking group and a drug
AU779869B2 (en) * 1999-04-13 2005-02-17 Nektar Therapeutics Pulmonary administration of dry powder formulations for treating infertility
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
ITRM20010079A1 (it) 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
ITRM20030196A1 (it) * 2003-04-24 2004-10-25 Sigma Tau Ind Farmaceuti Uso di reagenti per la preparazione di un medicamento
WO2006064283A1 (en) * 2004-12-17 2006-06-22 Cipla Limited Pharmaceutical compounds and compositions
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
CA2694391C (en) 2007-08-02 2019-02-26 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Oxidized avidin with high residency time in the treated tissues
EP2106806A1 (en) * 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticles for targeted delivery of active agents to the lung
TW201031436A (en) * 2009-02-16 2010-09-01 Univ Nat Taiwan Pharmaceutical composition for inhalation delivery and fabrication method thereof

Also Published As

Publication number Publication date
KR20140047668A (ko) 2014-04-22
UA114482C2 (uk) 2017-06-26
MX2014001176A (es) 2014-07-14
EP2739314B1 (en) 2019-05-22
PL2739314T3 (pl) 2019-09-30
KR101966630B1 (ko) 2019-04-09
DK2739314T3 (da) 2019-06-24
CN103717239A (zh) 2014-04-09
EP2739314A1 (en) 2014-06-11
PT2739314T (pt) 2019-06-21
ZA201401921B (en) 2015-05-27
CA2842276A1 (en) 2013-02-07
CA2842276C (en) 2020-11-24
US9872831B2 (en) 2018-01-23
MX355177B (es) 2018-04-09
NZ620202A (en) 2016-05-27
ES2729549T3 (es) 2019-11-04
BR112014002593A2 (pt) 2017-03-01
EA026453B1 (ru) 2017-04-28
JP6019118B2 (ja) 2016-11-02
IL230597A0 (en) 2014-03-31
AU2012292229B2 (en) 2017-08-03
US20140134106A1 (en) 2014-05-15
BR112014002593B1 (pt) 2022-11-29
AU2012292229A1 (en) 2014-02-13
WO2013017494A1 (en) 2013-02-07
CN103717239B (zh) 2017-08-01
JP2014521675A (ja) 2014-08-28

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
CY1120246T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
ECSP22051489A (es) Compuestos inhibidores de metaloenzimas
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1117678T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CY1117372T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους
GT201500011A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
PE20151788A1 (es) Inhibidores de bromodominios tetraciclicos
MX357939B (es) Terapia de combinacion de inhibidor de objetivo de rapamicina en mamifero/janus cinasa (mtor/jak).
ECSP14013159A (es) Compuestos inhibidores de metaloenzimas
BR112015029970A2 (pt) inibidores de cinase
EA201400986A1 (ru) Фармацевтические композиции, содержащие метформин и ингибитор dpp-4 или ингибитор sglt-2
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
MX2013006591A (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
CY1124331T1 (el) Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
IT1402018B1 (it) Formulazioni per il trattamento delle affezioni delle prime vie respiratorie.
LTPA2020511I1 (lt) Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui
BRPI0906606A2 (pt) Tratamento terapêutico para condições do pulmão.
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same

Legal Events

Date Code Title Description
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM